1. Home
  2. SURG vs INAB Comparison

SURG vs INAB Comparison

Compare SURG & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SurgePays Inc.

SURG

SurgePays Inc.

HOLD

Current Price

$0.47

Market Cap

13.8M

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.41

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SURG
INAB
Founded
2006
2016
Country
United States
United States
Employees
20
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.8M
15.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SURG
INAB
Price
$0.47
$1.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$6.00
AVG Volume (30 Days)
174.4K
66.7K
Earning Date
04-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$136.77
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$1.17
52 Week High
$3.45
$2.73

Technical Indicators

Market Signals
Indicator
SURG
INAB
Relative Strength Index (RSI) 38.64 40.08
Support Level N/A $1.35
Resistance Level $0.94 $1.85
Average True Range (ATR) 0.06 0.11
MACD -0.00 -0.03
Stochastic Oscillator 14.25 12.85

Price Performance

Historical Comparison
SURG
INAB

About SURG SurgePays Inc.

Surgepays Inc is a wireless and point of sale technology company focused on serving underserved and value-conscious consumers through a combination of retail distribution and digital acquisition channels. It provides mobile connectivity, financial technology services, and transaction processing solutions through an integrated platform that combines wireless services with point of sale software and retail distribution. It enables in-store and online activation of wireless services, prepaid top-ups, and financial transactions, allowing consumers to access essential services in both local and digital environments. Its segments are wireless services or MVNO Telecommunications, platform services or MVNE Enablement Platform (HERO), and wholesale enablement or Comprehensive Platform Services.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: